2586 Background: RNA modifications are involved in cancer initiation and progression. The
most abundant modification of mRNA is m6A generated by METTL3. Inhibition of METTL3 …

Introduction c-MET is an important therapeutic target for various cancers; however, the
People's Republic of China currently retails only one specific c-MET inhibitor. Our preclinical …

Background METTL3 is the RNA methyltransferase responsible for the deposition of N-6-
methyladenosine modification (m6A) on mRNA, to regulate its stability, splicing and protein …

Background This first-in-human study evaluated AMG 208, a small-molecule MET inhibitor,
in patients with advanced solid tumors. Methods Three to nine patients were enrolled into …

Summary References 1. Yankova et al. Small-molecule inhibition of METTL3 as a strategy
against myeloid leukaemia. Nature. 2021; 593 (7860): 597-601 2. Guirguis, Ofir-Rosenfeld …

Background CT053PTSA is a novel tyrosine kinase inhibitor that targets MET, AXL,
VEGFR2, FLT3 and MERTK. Here, we present preclinical data about CT053PTSA, and we …

Background: METTL3 is an RNA methyltransferase responsible for the deposition of N-6-
methyladenosine (m 6 A) modification on mRNA and long non-coding RNA (lncRNA) …

TPS2621 Background: MGCD516, is an orally-available, potent small molecule inhibitor of a
closely related family of RTKs including RET, TRK family, DDR2, MET, Axl family, KIT, as …

Aim: c-Met overexpression is associated with poor clinical prognosis. This dose-escalation
study (3+ 3 design; NCT01014936) evaluates the selective c-Met inhibitor MSC2156119J in …

2521^ Background: MSC2156119J, a selective c-Met inhibitor, suppresses tumor growth in
preclinical models. Methods: Primary endpoint of this dose-escalation study (3+ 3 design; …